Read this company snapshot
Daily valuation snapshot
Virax Biolabs Group Limited Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.87
- Market capitalization (USD)
- $1,490,367.56
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.2
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research VRAX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research VRAX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing VRAX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.87 |
| Market capitalization (USD) | $1,490,367.56 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.2 |
No matching rows. Clear the filter to see all records.
Read VRAX's valuation metrics
Company size
Virax Biolabs Group Limited Ordinary Shares's recorded market capitalization is $1,490,367.56. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
VRAX's recorded price-to-book ratio is 0.2. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Virax Biolabs Group Limited Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about VRAX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow VRAX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.